

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study



The Polaris Observatory HCV Collaborators*

Summary

Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013.

Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, $n=6754$) and genotype ($n=11\,342$) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data.

Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively).

Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections.

Funding John C Martin Foundation.

Introduction

Hepatitis C virus (HCV) infection is of growing international concern due to its substantial effect on morbidity and mortality.^{1–6} A leading cause of cirrhosis, hepatocellular carcinoma (HCC), liver transplantation, and liver-related death worldwide, the HCV-related disease burden continues to increase as the infected population advances to late stage liver disease.^{7,8} The disease inflicts an immense health and economic burden on countries due to the infection's hepatic and extrahepatic effects.^{9–14}

In 2016, the 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis infection by 2030,¹⁵ and WHO introduced global targets for the care and management of HCV including “a 90% reduction in new cases of chronic hepatitis C, a 65% reduction in hepatitis C deaths, and treatment of 80% of eligible people with chronic hepatitis C infections”.¹⁶ To achieve these goals, countries need to develop national policies based on up-to-date and reliable epidemiological evidence.^{17–19} However, data are often outdated and conflicting, making evidence-based policy making and resource allocation difficult. We aimed to review and analyse available data to estimate the current HCV disease burden at the national level to support countries in their efforts to develop national strategies.

In 2014, we estimated the global HCV prevalence and genotype distribution following a comprehensive review of indexed sources and grey literature (eg, government reports) published between 2000 and 2013.²⁰ The analysis focused on quantifying the number of viraemic infections (HCV RNA positive). By comparison, earlier studies^{21–23} had reported anti-HCV positive infections, which are serological evidence of past or present HCV infection. In 2015, the Polaris Observatory was created to monitor and forecast the disease burden for hepatitis B and C. This analysis builds on the previous efforts with an updated literature review and the addition of disease burden modelling to develop more accurate estimates of 2015 year-end viraemic HCV prevalence at the country level and aggregated to the global level.

Methods

This analysis represents the integration of a literature review, a Delphi process that used country expert interviews to identify missing inputs and to approve all inputs and outputs, and modelling to estimate the 2015 HCV prevalence. The details of data collection, scoring of data sources, Delphi process, and modelling, beyond the description in this section, are summarised in the appendix.

Lancet Gastroenterol Hepatol
2017; 2: 161–76

Published Online
December 15, 2016
[http://dx.doi.org/10.1016/S2468-1253\(16\)30181-9](http://dx.doi.org/10.1016/S2468-1253(16)30181-9)

See [Comment](#) page 146

*Collaborators listed at the end of the Article

Correspondence to:
Dr Homie Razavi, Center for Disease Analysis, Lafayette, CO 80026, USA
homie.razavi@centerforda.com

For the Polaris Observatory see
<http://polarisobservatory.com/>

See [Online](#) for appendix

Research in context

Evidence before this study

In 2014, we estimated the global prevalence and genotype distribution of hepatitis C virus (HCV) infection following a comprehensive review of indexed sources and grey literature (eg, government reports) published between 2000 and 2013. The analysis focused on quantifying the number of viraemic infections (HCV RNA positive). Three global prevalence studies published before 2014 followed a traditional systematic review and meta-analysis procedure and reported anti-HCV positive infections, which are serological evidence of past or present HCV infection.

Added value of this study

The present analysis represents both an update to and substantial expansion of previous efforts to quantify the HCV prevalence and disease burden. A Delphi process was used to complement a traditional systematic review by adding a level of validation through discussions with country experts. 400 experts were consulted to approve the inputs and outputs of 59 country models. This work is additionally unique in that it uses a disease burden model to forecast the 2015 year-end HCV prevalence, accounting for the impact of a changing population

due to ageing, treatment and cure, and mortality.

100 countries, representing more than 85% of the world's population, were included in the analysis. Data from these countries were used to estimate the regional prevalence, and regional prevalence rates were then applied to countries with missing data to estimate the global HCV prevalence.

Implications of all the available evidence

In 2016, the 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis infection by 2030, and the WHO introduced global targets for the care and management of HCV including “a 90% reduction in new cases of chronic hepatitis C, a 65% reduction in hepatitis C deaths, and treatment of 80% of eligible people with chronic hepatitis C infections”. The global HCV prevalence rate reported in this study is much lower than previous estimates have suggested. While some of this decline can be attributed to more recent (lower) prevalence estimates in Africa, increased mortality due to liver-related causes and an ageing population may have also contributed to a reduction in infections. The dissemination of the data presented here is crucial for the development of national and regional strategies to achieve these international targets.

Search strategy and selection criteria

We identified available data published between Jan 1, 2000, and March 31, 2016, through searches of PubMed, Embase, and non-indexed reports (appendix p 14). Non-indexed government reports, personal communication with country experts, and additional studies identified through manual searches of references noted in publications were included when better data were not available. The scope of the analysis included all countries. Articles were scored based on how well they could be extrapolated to the general population, the study sample size, and the year of analysis.²⁰

HCV disease burden modelling

From a methodological perspective, the biggest difference between our analysis and previous analyses is the use of a Markov model to estimate the HCV prevalence in 2015. The reason for this addition is that HCV prevalence changes over time.^{24–26} After culling and scoring available studies, a Microsoft Excel-based (version 2007) Markov-type model, described previously,^{24–26} was populated with the highest-scoring epidemiological data for the country of interest (appendix p 15).

For the approved models, a Delphi process was used to gain country expert consensus and validate inputs (appendix p 17). Experts were identified through HCV-related scientific contributions, or through referrals and recommendations from leading researchers. Two or more meetings were held to get consensus around input variables and outputs, and validate the outputs against available empirical data.

For the estimated models, for countries where meeting with local experts could not be scheduled, published estimates were used. All published studies were reviewed and scored by two epidemiologists, and the highest scored study was used for modelling (appendix pp 15–16). When input other than prevalence rate was unavailable for a country, input was extrapolated from countries within the same Global Burden of Disease (GBD) region.

GBD regional prevalence and genotype were calculated as the weighted average of the 2015 outputs from approved and estimated models, and the regional rates were then applied to the 2015 populations of countries with missing data to estimate the global HCV prevalence and genotypes. Countries without a formal GBD designation were assigned an imputed GBD region (appendix p 18).

Statistical analysis

Uncertainty intervals (UIs) and sensitivity analyses were done with Crystal Ball (release 11.1.3708.0), an Excel add-in by Oracle. Beta-PERT distributions²⁷ were used for all uncertain inputs. Monte Carlo simulation was used to estimate 95% UI. It was assumed that prevalence uncertainty estimates in all countries were independent. The uncertainty range for each country was calculated based on range inputs for prevalence, transition rates, and mortality rate (appendix pp 6–13, 19–23). These were used to calculate regional and global uncertainty ranges. For these estimates, two sources of uncertainty had to be taken into consideration—country-level uncertainty in prevalence

and its effect on the regional and global prevalence. The 2015 country prevalence estimates and 95% UIs were consolidated and defined as assumption variables. A 1/0 switch was developed to include or exclude countries from the regional prevalence calculation, and was also defined as an assumption. A sensitivity analysis was run to identify countries that accounted for the greatest variation in the base global prevalence through their estimated prevalence uncertainty and their inclusion in regional averages.

Role of the funding source

This study was funded by the John C Martin Foundation through the Polaris Observatory. The funders had no role in the study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript. CE, DR-S, HN, HR, IGa, IGo, JDS, JGu, KP, KR-S, KM, SB, and SR had access to the raw data. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

Results

We identified 9177 studies published between Jan 1, 2013, and March 31, 2016, through PubMed (n=4556) and Embase (n=4621) searches. Following the removal of duplicates (n=2408), 6754 studies were selected for review and inclusion in the final analysis. When combined with

prevalence studies published before 2013²⁰ and expert input, prevalence estimates were available for 113 countries, accounting for 92% of the world's population. Among all countries with a prevalence estimate, viraemic rate was available for 81 countries, and age and sex distributions were available for 89 countries, accounting for 82% and 85% of the world's population in 2015, respectively (appendix pp 19–23).

The literature search for genotype data identified 11342 studies through PubMed and Embase, and the results were combined with unpublished data provided by country experts. Genotype distribution was available for 115 countries (table 1; appendix pp 24–29), which accounted for 90% of the world's population in 2015. Models were built for 100 countries—the inputs and outputs for 59 countries were approved by country experts and for 41 countries were estimated using published data alone. To develop a model, at least one high quality prevalence study and one or more supporting inputs (ie, age and sex, genotype, viraemic rate, treatment rate) were necessary. The remaining countries had insufficient data to create a model.

Countries with approved and estimated modelled prevalence as well as countries for which prevalence was extrapolated from regional averages are shown in the appendix (p 30; figure 1), as are the quality scores of input prevalence data for approved and estimated countries. The 2015 viraemic HCV prevalence of the

	Viraemic prevalence, 2015*	Viraemic population (1000s), 2015*	Genotypes†									
			1a	1b	1c	1 (other)	2	3	4	5	6	Mixed or other
Asia Pacific, high income												
Japan	0.7% (0.3–0.8)	857 (364–1024)	0	64.8%	0	0	34.2%	0	0	0	0	1.0%
South Korea	0.5% (0.3–0.5)	231 (148–261)	3.0%	45.4%	0	4.3%	45.3%	0.8%	0.2%	0	1.0%	0
Asia, Central												
Armenia	..	..	5.2%	36.2%	0	1.7%	18.9%	38.0%	0	0	0	0
Azerbaijan	1.9% (1.3–2.1)	190 (125–212)	2.9%	64.2%	0	0	6.7%	26.0%	0.2%	0	0	0
Georgia	4.2% (3.0–4.2)	165 (120–169)	1.9%	37.6%	0	0	24.5%	34.3%	0	0	0	1.7%
Kazakhstan	2.8 (1.9–3.2)	508 (334–572)	2.5%	52.5%	0	0	10.0%	35.0%	0	0	0	0
Mongolia	6.4% (4.3–7.9)	194 (131–237)	0	98.8%	0	0	1.2%	0	0	0	0	0
Tajikistan	..	..	0	82.7%	0	0	5.8%	7.7%	0	0	0	3.8%
Uzbekistan	4.3% (3.0–5.0)	1292 (902–1524)	2.9%	64.2%	0	0	6.7%	26.0%	0.2%	0	0	0
Asia, East												
China	0.7% (0.5–0.8)	9795 (6675–10 832)	1.4%	56.8%	0	0	15.4%	8.7%	0	0	6.3%	11.4%
Hong Kong	0.2% (0.1–0.3)	15 (6–22)	4.3%	62.4%	0	0	3.2%	2.8%	0	0	27.4%	0
Taiwan	2.1% (1.3–3.7)	489 (310–877)	2.6%	45.5%	0	0.7%	39.5%	1.0%	0.2%	0	0.5%	10.1%
Asia, South												
Afghanistan	0.5% (0.3–0.8)	181 (85–258)	35.2%	2.8%	0	0	0	62.0%	0	0	0	0
India	0.5% (0.4–0.8)	6245 (4748–10 957)	9.0%	16.1%	0	3.3%	0	64.1%	7.3%	0.3%	0	0
Nepal	..	..	11.3%	6.6%	0	21.4%	0	58.4%	0	0	0	2.4%
Pakistan	3.8% (2.8–3.9)	7172 (5363–7487)	4.8%	1.2%	0	1.0%	3.8%	79.0%	1.6%	0.1%	0.1%	8.3%
(Table 1 continues on next page)												

(Table 1 continues on next page)

	Viraemic prevalence, 2015*	Viraemic population (1000s), 2015*	Genotypes†									
			1a	1b	1c	1 (other)	2	3	4	5	6	Mixed or other
(Continued from previous page)												
Asia, Southeast												
Cambodia	1.6% (0.9–1.7)	257 (147–272)	0	24.0%	0	0	0	20.0%	0	0	56.0%	0
Indonesia	0.5% (0.2–0.8)	1289 (443–2046)	25.6%	39.0%	0	3.0%	9.3%	9.4%	3.6%	0	0	10.0%
Laos	..	..	0	4.4%	0	0	0	0	0	0	95.6%	0
Malaysia	1.2% (0.8–1.3)	382 (240–405)	0	0	0	35.8%	0.7%	62.3%	0.7%	0	0.4%	0
Myanmar	..	..	4.1%	6.9%	0	0	0.7%	39.3%	0	0	49.0%	0
Philippines	0.6% (0.3–0.6)	614 (353–651)	70.7%	2.5%	0	0	26.4%	0	0.2%	0	0.2%	0
Sri Lanka	..	..	0	46.9%	0	0	37.5%	0	0	0	0	15.6%
Thailand	0.7% (0.4–0.7)	463 (255–487)	4.4%	13.0%	0	0	0	47.8%	0	0	34.8%	0
Vietnam	1.1% (0.6–1.2)	1066 (580–1116)	30.0%	17.1%	0	0	1.1%	1.1%	0	0	50.8%	0
Australasia												
Australia	1.0% (0.7–1.0)	230 (178–244)	18.5%	15.7%	0	15.4%	5.6%	42.2%	1.3%	0	1.1%	0.2%
New Zealand	1.0% (0.6–1.3)	48 (30–62)	44.0%	11.0%	0	0	7.0%	35.0%	0	0	1.0%	2.0%
Caribbean												
Cuba	0.3% (0.1–0.7)	35 (14–77)	17.0%	81.0%	0	0	0	0	0	0	0	2.0%
Dominican Republic	0.6% (0.4–1.0)	68 (42–108)	58.9%	19.4%	0	3.7%	9.6%	0.5%	0.2%	0	0	7.7%
Guadeloupe	0.3% (0.2–0.6)	1 (1–3)	0	0	0	80.0%	0	20.0%	0	0	0	0
Martinique	..	..	23.6%	56.7%	0.9%	0	6.9%	7.8%	3.6%	0.3%	0.3%	0
Suriname	..	..	0	0	0	0	100.0%	0	0	0	0	0
Europe, Central												
Albania	..	..	6.0%	50.0%	0	0	20.0%	8.0%	16.0%	0	0	0
Bosnia and Herzegovina	..	..	4.0%	69.3%	0	0	4.0%	21.3%	1.3%	0	0	0
Bulgaria	1.2% (0.7–1.6)	87 (46–122)	5.3%	72.3%	0	0	0	11.6%	0	0	0	10.8%
Croatia	0.6% (0.4–0.7)	26 (17–28)	13.1%	37.4%	0	8.3%	2.2%	35.6%	3.4%	0	0	0
Czech Republic	0.4% (0.2–0.5)	43 (22–49)	13.2%	52.8%	0	0	0.5%	31.1%	2.4%	0	0	0
Hungary	0.5% (0.3–0.6)	52 (29–55)	9.1%	79.9%	0	1.6%	0.9%	6.7%	1.7%	0.1%	0	0
Macedonia	..	..	0	0	0	55.4%	0	44.6%	0	0	0	0
Montenegro	..	..	19.6%	35.0%	0	0	1.1%	24.7%	19.6%	0	0	0
Poland	0.5% (0.4–0.6)	184 (136–224)	2.0%	83.0%	0	0	0.1%	10.0%	4.9%	0	0	0
Romania	2.5% (1.8–2.6)	547 (397–566)	5.4%	92.6%	0	0	0	0.8%	1.2%	0	0	0
Serbia	..	..	0	0	0	57.9%%	3.7%	23.2%	6.7%	0	0	8.5%
Slovakia	0.6% (0.4–0.7)	33 (20–37)	0	0	0	89.9%	1.5%	6.6%	0.5%	0	0.5%	1.0%
Slovenia	0.3% (0.2–0.3)	6 (4–7)	6.9%	8.2%	0	53.0%	2.1%	29.3%	0.4%	0.1%	0	0
Europe, Eastern												
Belarus	..	..	5.0%	53.2%	0	0	2.5%	25.7%	13.6%	0	0	0
Estonia	1.4% (0.9–1.6)	18 (12–20)	1.0%	71.7%	0	0	3.0%	24.2%	0	0	0	0
Latvia	2.2% (1.4–2.6)	43 (28–50)	46.1%	4.3%	0	13.4%	3.6%	31.9%	0.7%	0	0	0
Lithuania	1.1% (0.7–1.3)	33 (20–39)	2.1%	69.3%	0	3.8%	5.6%	19.2%	0	0	0	0
Russia	3.3% (2.3–3.5)	4748 (3238–4960)	2.1%	52.8%	0	0	8.1%	36.3%	0.1%	0	0	0.6%
Ukraine	..	..	1.6%	42.1%	0	0	1.6%	28.8%	0.8%	0	0	25.1%
Europe, Western												
Austria	0.2% (0.1–0.4)	21 (6–30)	20.0%	52.0%	0	0	5.0%	19.0%	4.0%	0	0	0
Belgium	0.6% (0.2–0.7)	64 (23–75)	0	50.0%	0	9.0%	6.0%	19.0%	14.0%	2.0%	0	0
Denmark	0.3% (0.3–0.3)	19 (14–20)	34.0%	12.0%	0	0	8.0%	43.0%	3.0%	0	0	0
Finland	0.4% (0.3–0.5)	23 (16–26)	10.2%	11.6%	0	3.3%	11.4%	48.8%	0.9%	0.1%	0.1%	13.6%

(Table 1 continues on next page)

(Table 1 continues on next page)

	Viraemic prevalence, 2015*	Viraemic population (1000s), 2015*	Genotypes†									
			1a	1b	1c	1 (other)	2	3	4	5	6	Mixed or other
(Continued from previous page)												
France	0.3% (0.1-0.3)	194 (93-222)	14.8%	29.7%	0	15.3%	9.1%	19.7%	9.2%	2.0%	0.2%	0
Germany	0.3% (0.1-0.4)	205 (90-313)	25.0%	33.0%	0	4.0%	6.4%	27.4%	3.3%	0.2%	0.2%	0
Greece	1.1% (0.7-1.5)	132 (82-169)	11.5%	28.4%	0.2%	5.1%	7.0%	34.0%	13.9%	0	0	0
Iceland	0.3% (0.2-0.4)	1 (1-1)	41.1%	1.8%	0	0	0.8%	55.3%	1.0%	0	0	0
Ireland	0.6% (0.4-0.9)	30 (20-42)	42.0%	14.0%	0	0	4.0%	39.0%	1.0%	0	0	0
Israel	1.2% (0.7-1.3)	100 (60-103)	12.0%	57.0%	0	0	8.0%	20.0%	3.0%	0	0	0
Italy	1.1% (0.7-2.7)	680 (455-1641)	11.0%	44.0%	0	3.0%	15.0%	10.0%	7.0%	0	0	10.0%
Luxembourg	0.9% (0.6-1.0)	5 (3-6)	0	0	0	55.3%	4.3%	33.6%	6.4%	0	0	0
Malta	0.3% (0.2-0.4)	1 (1-2)	45.0%	15.0%	0	0	1.0%	37.0%	2.0%	0	0	0
Netherlands	0.1% (0.0-0.2)	16 (5-26)	14.8%	15.6%	0	18.8%	9.7%	29.3%	10.5%	0	0	1.3%
Norway	0.4% (0.3-0.5)	21 (15-24)	18.0%	18.0%	0	4.0%	9.0%	50.0%	1.0%	0	0	0
Portugal	0.8% (0.7-1.1)	89 (74-120)	42.7%	21.4%	0	4.0%	1.3%	17.9%	12.5%	0	0	0.2%
Spain	0.8% (0.3-1.2)	386 (159-557)	24.0%	53.5%	0	0	2.0%	8.2%	9.7%	0	0	2.5%
Sweden	0.4% (0.3-0.4)	38 (28-43)	40.0%	10.0%	0	0	20.0%	30.0%	0	0	0	0
Switzerland	1.0% (0.6-1.1)	78 (45-87)	26.0%	26.0%	0	0	8.5%	29.2%	10.3%	0	0	0
UK	0.3% (0.1-0.3)	189 (91-211)	24.4%	11.9%	0	8.8%	7.3%	43.8%	3.8%	0	0	0
Latin America, Andean												
Peru	0.5% (0.3-0.6)	167 (99-182)	74.0%	12.0%	0	0	2.0%	10.0%	0	0	0	2.0%
Latin America, Central												
Colombia	0.8% (0.6-0.9)	409 (272-436)	5.7%	82.8%	0	0	8.5%	2.8%	0	0	0	0
Mexico	0.4% (0.3-0.5)	532 (304-557)	45.4%	24.9%	0	0	21.8%	7.2%	0.3%	0.1%	0	0
Panama	0.3% (0.2-0.3)	12 (7-14)	..	..	..	..	..	..	..	..	..	..
Venezuela	0.4% (0.2-0.4)	118 (59-126)	37.0%	26.0%	0	0.4%	33.0%	4.0%	0	0	0	0
Latin America, Southern												
Argentina	0.8% (0.3-1.2)	326 (144-490)	20.3%	38.1%	0	0.8%	21.7%	17.8%	1.3%	0	0	0
Chile	0.3% (0.2-0.5)	57 (31-94)	7.9%	72.7%	0	0	2.0%	16.5%	0.6%	0.3%	0.1%	0
Latin America, Tropical												
Brazil	0.9% (0.6-0.9)	1787 (1293-1896)	31.0%	33.4%	0	0.4%	4.6%	30.2%	0.2%	0.1%	0	0
North Africa/Middle East												
Algeria	1.0% (0.3-1.7)	388 (140-674)	1.4%	86.2%	0	1.2%	8.5%	0.9%	1.2%	0.2%	0	0.5%
Bahrain	1.2% (0.8-1.3)	17 (11-18)	14.1%	21.1%	0	1.6%	3.9%	15.6%	25.0%	0	0	18.8%
Egypt	6.3% (4.5-6.7)	5625 (4007-6044)	0	4.0%	0	6.0%	0	0	90.0%	0	0	0
Iran	0.2% (0.2-0.3)	199 (129-226)	39.7%	12.1%	0	1.3%	1.4%	27.7%	0.9%	0	0	16.9%
Iraq	0.2% (0.2-0.3)	85 (60-97)	1.4%	12.9%	0	0	0	17.1%	52.9%	0	0	15.7%
Jordan	0.3% (0.1-0.4)	25 (11-29)	23.1%	19.2%	0	0	0	0	57.7%	0	0	0
Kuwait	..	..	0	0	0	15.0%	2.5%	2.5%	80.0%	0	0	0
Lebanon	0.2% (0.1-0.4)	8 (3-18)	6.6%	40.4%	0	0	3.7%	14.1%	33.8%	1.4%	0.1%	0
Libya	0.7% (0.5-0.7)	42 (32-43)	4.2%	6.4%	0	6.9%	7.0%	7.4%	14.6%	0	0	53.5%
Morocco	0.8% (0.5-0.9)	263 (190-328)	6.5%	40.3%	0	0	41.6%	1.0%	0.6%	0.1%	0	10.0%
Oman	0.4% (0.3-0.4)	16 (12-18)	5.5%	30.0%	0	10.1%	2.1%	32.6%	16.5%	0	0	3.2%
Occupied Palestinian territory	..	..	18.5%	9.8%	0	0	0	0	64.1%	0	0	7.6%
Qatar	1.6% (1.3-1.8)	38 (30-40)	1.9%	10.7%	0	3.6%	0.9%	10.3%	72.4%	0.1%	0	0
Saudi Arabia	0.3% (0.2-0.9)	105 (79-189)	0	0	0	38.6%	3.6%	5.2%	52.6%	0	0	0
Syria	3.0% (1.3-3.5)	554 (245-653)	3.4%	18.8%	0	6.3%	0.8%	1.8%	59.0%	10.0%	0	0

(Table 1 continues on next page)

(Table 1 continues on next page)

	Viraemic prevalence, 2015*	Viraemic population (1000s), 2015*	Genotypes†									
			1a	1b	1c	1 (other)	2	3	4	5	6	Mixed or other
(Continued from previous page)												
Tunisia	0.9% (0.2–1.1)	108 (25–123)	5.1%	76.6%	0	0	5.1%	3.7%	7.3%	0	0	2.2%
Turkey	0.6% (0.3–1.0)	492 (271–763)	12.9%	80.4%	0	0	1.5%	3.7%	1.5%	0	0	0
United Arab Emirates	1.3% (0.5–1.6)	131 (50–159)	5.4%	9.4%	0	25.6%	2.2%	35.0%	22.0%	0	0	0
Yemen	0.8% (0.5–0.9)	211 (143–258)	..	..	..	..	..	..	..	..	..	..
North America, high income												
Canada	0.6% (0.4–0.7)	212 (136–246)	36.5%	21.5%	0	6.1%	14.1%	20.2%	0.3%	0	0	1.3%
Puerto Rico	1.0% (0.6–1.6)	36 (23–60)	39.8%	27.1%	0	15.2%	12.1%	3.8%	1.8%	0	0.2%	0
USA	0.9% (0.7–1.2)	2936 (2231–3826)	46.2%	26.3%	0	0	10.7%	8.9%	6.3%	..	1.1%	0.5%
Oceania												
Fiji	0.1% (0.0–0.3)	1 (0.2–3)	..	..	..	..	..	..	..	..	..	..
Papua New Guinea	1.2% (0.9–4.2)	94 (70–328)	..	..	..	..	..	..	..	..	..	..
Samoa	0.1% (0.1–0.2)	0.2 (0.1–0.4)	..	..	..	..	..	..	..	..	..	..
Sub-Saharan Africa, Central												
Central African Republic	0.3% (0.2–0.4)	16 (11–18)	0	0	0	0	8.6%	8.6%	82.8%	0	0	0
DR Congo	..	..	0	0	0	0	3.2%	0	96.8%	0	0	0
Equatorial Guinea	..	..	0	0	0	35.0%	1.7%	3.3%	60.0%	0	0	0
Gabon	7.0% (5.1–7.3)	124 (90–129)	0	0	0	5.8%	2.2%	0	92.0%	0	0	0
Sub-Saharan Africa, East												
Burundi	1.0% (0.8–4.0)	120 (93–459)	5.6%	0	0	0	0	1.7%	92.7%	0	0	0
Ethiopia	0.6% (0.4–0.7)	647 (410–726)	8.8%	2.7%	0	2.0%	13.5%	9.5%	60.0%	0	0	3.5%
Kenya	0.2% (0.1–0.3)	115 (42–126)	10.0%	0	0	0	90.0%	0	0	0	0	0
Madagascar	0.2% (0.2–0.3)	56 (39–81)	0	52.9%	0	0	47.1%	0	0	0	0	0
Mozambique	..	..	27.8%	22.2%	0	0	0	22.2%	0	27.8%	0	0
Sub-Saharan Africa, Southern												
South Africa	0.7% (0.4–0.9)	356 (227–441)	2.3%	22.1%	0	7.1%	1.2%	12.6%	12.4%	35.7%	0	6.7%
Sub-Saharan Africa, West												
Burkina Faso	1.3% (1.0–1.4)	247 (189–256)	3.1%	9.4%	0	0	56.3%	15.6%	3.1%	0	0	12.5%
Cameroon	0.7% (0.5–0.8)	164 (117–184)	0	0	0	40.0%	20.0%	0	40.0%	0	0	0
Chad	1.1% (0.8–1.3)	162 (111–184)	0	0	0	7.7%	7.7%	0	84.6%	0	0	0
The Gambia	0.8% (0.5–1.3)	17 (10–27)	0	0	0	19.4%	58.1%	6.5%	0	0	0	16.1%
Ghana	1.4% (1.1–3.4)	399 (305–944)	0.1%	0.2%	0	12.8%	87.0%	0	0	0	0	0
Guinea-Bissau	..	..	0	0	0	1.8%	98.2%	0	0	0	0	0
Nigeria	1.4% (1.0–1.4)	2553 (1902–2651)	0	0	0	82.3%	5.9%	7.4%	4.4%	0	0	0
*2015 year-end estimate is a model output projection based on historic data. †Genotype distribution data are either taken from the literature or based on regional averages in the absence of country-specific data.												
Table 1: Modelled 2015 hepatitis C viraemic prevalence and chronically infected population (all ages) and genotype distribution												

*2015 year-end estimate is a model output projection based on historic data. †Genotype distribution data are either taken from the literature or based on regional averages in the absence of country-specific data.

Table 1: Modelled 2015 hepatitis C viraemic prevalence and chronically infected population (all ages) and genotype distribution

same countries is shown in figure 1A, while the prevalence of all countries, including those with an extrapolated prevalence, is shown in figure 1B. The number of HCV infections by country is shown in figure 1C. The numerical prevalence and total infections for approved and estimated countries are shown in table 1. The model input data for prevalence, quality score, year of prevalence estimate, uncertainty range, viraemic rate, source of prevalence age distribution, and all corresponding references are included in the appendix (pp 19–23).

The global prevalence of viraemic HCV is estimated to be 1.0% (95% UI 0.8–1.1) in 2015, corresponding to 71.1 million (62.5–79.4) viraemic infections. Regional estimates for HCV prevalence in 2015 are shown in table 2. The countries that accounted for 80% of total global HCV infections are shown in figure 2.

The top ten country-level uncertainties that made the largest contribution to the global uncertainty are shown in figure 3. The top ten uncertainties listed account for 92% of the total variance in the global prevalence. The uncertainty in the total number of infections in India




Figure 1: HCV prevalence estimates (end of 2015)

2015 viraemic prevalence in countries with approved or estimated models (A), viraemic prevalence in all countries (B), and number of viraemic infected people in all countries (C). HCV=hepatitis C virus.

	Viraemic HCV prevalence (95% UI)	Population (millions)	Viraemic HCV infected (millions; [95% UI])
Asia Pacific, high income	0.6% (0.3–0.7)	183	1.1 (0.6–1.3)
Asia, Central	3.6% (2.8–3.9)	88	3.2 (2.5–3.4)
Asia, East	0.7% (0.5–0.8)	1439	10.5 (7.3–11.6)
Asia, South	0.9% (0.7–1.3)	1742	15.3 (12.3–22.7)
Asia, Southeast	0.7% (0.5–0.8)	654	4.7 (3.2–5.2)
Australasia	1.0% (0.8–1.0)	29	0.3 (0.2–0.3)
Caribbean	0.5% (0.4–0.8)	45	0.2 (0.2–0.4)
Europe, Central	1.0% (0.8–1.0)	118	1.2 (0.9–1.2)
Europe, Eastern	3.3% (2.1–3.4)	206	6.7 (4.2–7.0)
Europe, Western	0.5% (0.4–0.8)	426	2.3 (1.9–3.2)
Latin America, Andean	0.5% (0.3–0.6)	59	0.3 (0.2–0.3)
Latin America, Central	0.5% (0.4–0.5)	247	1.3 (0.9–1.3)
Latin America, Southern	0.6% (0.3–0.9)	64	0.4 (0.2–0.6)
Latin America, Tropical	0.9% (0.6–0.9)	211	1.8 (1.3–2.0)
North Africa/Middle East	1.7% (1.4–1.9)	498	8.5 (6.8–9.2)
North America, high income	0.9% (0.7–1.1)	362	3.2 (2.4–4.0)
Oceania	1.1% (0.8–3.7)	11	0.1 (0.1–0.4)
Sub-Saharan Africa, Central	2.1% (0.1–6.9)	115	2.4 (0.1–8.0)
Sub-Saharan Africa, East	0.5% (0.4–0.7)	425	2.1 (1.6–2.9)
Sub-Saharan Africa, Southern	0.7% (0.4–0.9)	76	0.5 (0.3–0.7)
Sub-Saharan Africa, West	1.3% (1.1–1.4)	399	5.1 (4.3–5.7)
Total	1.0% (0.8–1.1)	7397	71.1 (62.5–79.4)

HCV=hepatitis C virus. UI=uncertainty interval.

Table 2: Regional prevalence and number of infected individuals (all ages)




Figure 2: Countries accounting for 80% of the total viraemic HCV infections
HCV=hepatitis C virus.

had the largest effect on our forecast. If the total number of infections in India is 11.0 million, rather than 6.2 million, the global estimate would be 76.6 million infections instead of 71.1 million. This takes into account the additional infections in India as well as the effect of India's prevalence on the regional prevalence, which is then applied to countries without data.

Removing India's prevalence completely and using the regional prevalence instead (for India and other countries in the region without data) was the third largest driver of uncertainty. The global prevalence would be 75.9 million in this case, because other countries in the region (with data) have a higher prevalence than India, and regional prevalence is dampened by India. A similar observation is made in sub-Saharan Africa, Central region, where only the Central African Republic (prevalence 0.3%) and Gabon (7.04%) had reported prevalence estimates. Removing Central African Republic from the analysis would result in Gabon being used for the regional average and an estimate of 76.7 million infections globally (figure 3).

A separate sensitivity analysis looked at the effect of excluding estimated countries from the analysis and basing the global prevalence on approved countries only. In this scenario, the estimated global prevalence would be 0.7% (95% CI 0.6–0.8) with a total number of HCV infections of 38 million (34–41).

The HCV genotype distribution of the modelled countries is shown in table 1. These distributions were based on published studies referenced in the appendix (pp 24–29). Appendix p 29 contains data for data quality scores of the underlying study and sources for genotype 1a/b breakout if they were not reported in the primary study. The estimated genotype distribution by GBD region is shown in figure 4A, while the data are combined with total viraemic HCV infections by GBD region and shown in figure 4B. At the global level, genotype 1 dominated (44% of all infections), followed by genotype 3 (25%) and genotype 4 (15%). Genotype 1 dominated in high-income and upper-middle income countries (60% of all infections), whereas genotype 3 (36%) was common in lower middle-income countries, and genotype 4 (45%) was common in low-income countries.

Discussion

Our analysis represents both an update to and substantial expansion of previous efforts to quantify the HCV prevalence and disease burden. A Delphi process was used to complement a traditional systematic review by adding a level of validation through discussions with country experts. 400 experts were consulted to approve the inputs and outputs of 59 country models. This work is additionally unique in that it uses a disease burden model to forecast the 2015 year-end HCV prevalence, accounting for the impact of a changing population due to ageing, treatment and cure, and mortality.

The 2015 global prevalence estimate of 1.0% (95% CI 0.8–1.1) or 71.1 million (62.5–79.4) infections is substantially lower than that in previous estimates.^{22,23} Previous studies were based on older and higher prevalence estimates for China and India (appendix p 31). However, the more recent studies^{17,28} show a much lower infection rate in these countries. In addition,

most studies are done in the adult population; however, when estimates are applied to a country's total population, disease burden is overestimated. Furthermore, the earlier studies reported anti-HCV prevalence that is evidence of past or present infection rather than active infection. Our previous estimate took all these factors into account for a global estimate of 80 million (95% CI 64–103) viraemic infections.²⁰ Since the last study, we completed interviews in 59 countries, and Nigeria and Cameroon reported much lower HCV prevalence based on unpublished national studies. This reduced the overall prevalence in the region. In addition, the modelling took into consideration the effect of mortality (liver related and all cause) and treatment. The overall effect was a reduction in the global prevalence estimate, which was still within the uncertainty intervals of our previous estimate.²⁰ The current estimate reports a more narrow uncertainty range as a result of the updated methodology and incorporating country interviews.

Modelling the prevalence captured the change in the epidemiology of HCV infection. Globally, the total number of viraemic HCV infections has been decreasing since 2007 (appendix p 31); however, there were major variations between regions. Of the modelled countries, ten showed a 10% or greater growth in prevalence since 2007 due to foreign workforce from endemic countries (Qatar and the United Arab Emirates), iatrogenic infections (Azerbaijan, India, Iraq, Syria, and Uzbekistan), and infections among people who inject drugs (Iran, Russia, and Latvia). In most other countries, the rate of mortality (the rate of all-cause and liver related) was higher than new infections, leading to a decrease in total infections. Historically, prevalence was increasing in every region until blood screening started in early to mid-1990s.

However, development of an accurate global estimate remains a problem because of scarcity and low quality of data. Of 250 recognised countries in the world, HCV prevalence estimates were available for 113 countries (not all countries were modelled due to lack of available secondary data needed for a model). Globally, 91 countries have a population less than 1.5 million and only eight of these countries reported their HCV prevalence. 92 (60%) of the countries with a larger population had HCV prevalence studies. Of these, 21 countries had studies with a quality score of 3, 49 had a quality score of 2, and 22 had a quality score of 1 (appendix pp 19–23, 30). 13 of the countries with a quality score of 1 were in Europe and included Austria, Belgium, Finland, Germany, Italy, Portugal, and Norway, and 20 were high-income countries. Thus, the quality of the epidemiology data did not correlate with countries' income and robust national surveillance studies in the general population are needed to better quantify HCV burden. Larger countries had much larger effect on the global estimates. China (quality score=3), Pakistan




Figure 3: Sensitivity analysis of 2015 global HCV prevalence viraemic infections, all ages (top 10)

(score=3), India (score=1), Egypt (score=3), Russia (score=2), and USA (score=3) accounted for 51% of total HCV infections globally (figure 2).

The prevalence range (the estimated prevalence and accompanying UI) reported here attempts to capture all uncertainties considered. Future revisions to the prevalence range will most probably come from estimates for countries without reported studies (grey countries in figure 1A), which included a large number of countries in Africa as well as some in Central and South America and Eastern Europe. As shown above, country interviews can provide more recent unpublished prevalence estimates. To test the effect of having approved estimates, a sensitivity analysis was done in which all estimated (non-approved) countries were removed from the analysis. In this scenario, the total estimated number of infections (globally) was 38 million. This result could be explained by a selection bias as a result of interviews being conducted in countries with a low prevalence.

Overall, care was taken to minimise biases that could have the largest effect on the global estimate. In 59 countries, interviews with country experts were used to identify relevant unpublished data and approve inputs and outputs. Panel meetings run the risk of confirmation, observer, and recall bias; however, facilitator training and meeting structure were designed to minimise the effect of these biases. Over the course of the project, ten facilitators were trained to lead country interviews. Each meeting required two attendees, one facilitator, and one note-taker. After each meeting, the note-taker provided feedback on how to improve future facilitations. In addition, for all models, the data inputs, model calibration, and outputs were reviewed by a second independent epidemiologist before being incorporated into the global estimate.




Figure 4: Genotype distribution

By GBD region (A) and HCV genotype and total infected by GBD region (B). GBD=Global Burden of Disease.

The genotype distribution, by region, did not change substantially (figure 4) since the last study²⁰ with the exception of further refinement of data for genotype 1. When genotype 1a and 1b data were not available in the highest scored study, secondary studies were used. This refinement was requested by experts because these

subgenotypes still show a different response rate to the available therapies. A new analysis was also added (figure 4B) that combined genotypes and total infections by region. The broad distribution of genotypes across different income settings highlights the importance of pan-genotypic therapies for elimination of HCV.

Many of the limitations of the original study²⁰ were addressed here; however, several limitations remained. As mentioned above, availability of data and the quality of available data limited the accuracy of the forecasts (especially in sub-Saharan Africa). Ranges were used to address the uncertainty in the available data. Additionally, in the modelled countries the treated population was segmented by genotype proportionally to the genotype distribution of the HCV-infected population. If individuals with specific genotypes were treated preferentially, then the genotype distribution of the prevalent population could be different than what is forecasted here. The use of a model to forecast 2015 HCV prevalence introduced another limitation—the accuracy of the model. When available, the outputs of the model were validated against empirical data to reduce errors due to the modelling. However, another limitation was the uncertainty in empirical data. Two recent studies have shown that cases of hepatocellular carcinoma are under-reported by 37–50% in Sweden and Melbourne, Australia.^{29,30} This would result in an underestimation of cases of hepatocellular carcinoma by our models.

We forecast a continual decline in total HCV infections as we move forward. In 2015, an estimated 950 000 patients were treated for HCV, with two-thirds of those treatments with direct acting antivirals.²⁴ An estimated 700 000 individuals achieved sustained viral response and were removed from the infected population. This accounts for only 1% of the total infected population who are treated and cured annually. However, as countries develop their national hepatitis elimination strategies and expand prevention, screening, and treatment, a more rapid decline in total viraemic infections is forecasted.

Contributors

CE, DR-S, HN, HR, IGA, IGO, JGu, JDS, KP, KR-S, KM, SB, and SR prepared the first draft and finalised the draft based on comments from other authors. All other authors provided data, analysed data, reviewed results, provided guidance on methodology, and provided critical feedback on the report.

The Polaris Observatory HCV Collaborators

Sarah Blach, Stefan Zeuzem, Michael Manns, Ibrahim Altraif, Ann-Sofi Duberg, David H Muljono, Imam Waked, Seyed M Alavian, Mei-Hsuan Lee, Francesco Negro, Faisal Abaalkhail*, Ahmed Abdou*, Maheeba Abdulla*, Antoine Abou Rached*, Inka Aho*, Ulus Akarca*, Imad Al Ghazzawi*, Saad Al Kaabi*, Faryal Al Lawati*, Khalid Al Namaani*, Youssif Al Serkal*, Said A Al-Busafi*, Layla Al-Dabal*, Soo Aleman*, Abdullah S Alghamdi*, Abdulrahman A Aljumah*, Hamad E Al-Romaihi*, Monique I Andersson*, Vic Arendt*, Perttu Arkila*, Abdullah M Assiri*, Oidov Baatarkhuu*, Abate Bane*, Ziv Ben-Ari*, Colm Bergin*, Fernando Bessone*, Florian Bihl*, Abdul R Bizri*, Martin Blachier*, Antonio J Blasco*, Carlos E Brandão Mello*, Philip Bruggmann*, Cheryl R Brunton*, Filipe Calinas*, Henry L Y Chan*, Asad Chaudhry*, Hugo Cheinquer*, Chien-Jen Chen*, Rong-Nan Chien*, Moon Seok Choi*, Peer B Christensen*, Wan-Long Chuang*, Vladimir Chulanov*, Laura Cisneros*, Mette R Clausen*, Matthew E Cramp*, Antonio Craxi*, Esther A Croes*, Olav Dalgard*, Jorge R Daruich*, Victor de Ledinghen*, Gregory J Dore*, Manal H El-Sayed*, Gul Ergör*, Gamal Esmat*, Chris Estes*, Karolin Falconer*, Elmoubashar Farag*, Maria L G Ferraz*, Paulo R Ferreira*, Robert Flisiak*, Sona Frankova*,

Ivane Gamkrelidze*, Ed Gane*, Javier García-Samaniego*, Amir Ghafoor Khan*, Ilias Gountas*, Adrian Goldis*, Magnús Gottfredsson*, Jason Grebely*, Michael Gschwanter*, Mário Guimarães Pessôa*, Jessie Gunter*, Behzad Hajarizadeh*, Omer Hajelssedig*, Saeed Hamid*, Waseem Hamoudi*, Angelos Hatzakis*, Sayed M Himatt*, Harald Hofer*, Irena Hrstic*, Yee-Tak Hui*, Bela Hunyady*, Ramazan Idilman*, Wasim Jafri*, Rohani Jahis*, Naveed Z Janjua*, Peter Jarčuška*, Agita Jeruma*, Jón G Jonasson*, Yasser Kamel*, Jia-Horng Kao*, Sabahattin Kaymakoglu*, David Kershenovich*, Jawad Khamis*, Young S Kim*, Loretta Kondili*, Zaher Koutoubi*, Mel Krajden*, Henrik Krarup*, Moon-sing Lai*, Wim Laleman*, Wai-cheung Lao*, Daniel Lavanchy*, Pablo Lázaro*, Henri Leleu*, Olufunmilayo Lesi*, Laurentius A Lesmana*, Michael Li*, Valentina Liakina*, Young-Suk Lim*, Boris Luksic*, Adam Mahomed*, Matti Maimets*, Mihály Makara*, Abraham O Malu*, Rui T Marinho*, Paul Marotta*, Stefan Mauss*, Muhammad S Memon*, Maria C Mendes Correa*, Nahum Mendez-Sanchez*, Shahin Merat*, Ammal M Metwally*, Rosmawati Mohamed*, Christophe Moreno*, Fadi H Mourad*, Beat Mühlhaupt*, Kimberly Murphy*, Helen Nde*, Richard Njouom*, Diana Nonkovic*, Suzanne Norris*, Solomon Obekpa*, Stephen Oguiche*, Sigurður Olafsson*, Marian Oltman*, Ogu Omede*, Casimir Omuemu*, Ohene Opare-Sem*, Anne L H Øvrehus*, Shirley Owusu-Ofori*, Tsendsuren S Oyunsuren*, George Papatheodoridis*, Ken Pasini*, Kevork M Peltekian*, Richard O Phillips*, Nikolay Pimenov*, Hossein Poustchi*, Nishi Prabdial-Sing*, Huma Qureshi*, Alnoor Ramji*, Devin Razavi-Shearer*, Kathryn Razavi-Shearer*, Berhane Redae*, Henk W Reesink*, Ezequiel Ridruejo*, Sarah Robbins*, Lewis R Roberts*, Stuart K Roberts*, William M Rosenberg*, Françoise Roudot-Thoraval*, Stephen D Ryder*, Rifaat Safadi*, Olga Sagalova*, Riina Salupere*, Faisal M Sanai*, Juan F Sanchez Avila*, Vivek Saraswat*, Rui Sarmento-Castro*, Christoph Sarrazin*, Jonathan D Schmelzer*, Ivan Schréter*, Carole Seguin-Devaux*, Samir R Shah*, Ala I Sharara*, Manik Sharma*, Anatoly Shevaldin*, Gamal E Shihai*, William Sievert*, Mark Sonderup*, Kyriakos Souliotis*, Danute Speiciene*, Jan Sperl*, Peter Stärkel*, Rudolf E Stauber*, Catherine Stedman*, Daniel Struck*, Tung-Hung Su*, Vana Sypsa*, Soek-Siam Tan*, Junko Tanaka*, Alexander J Thompson*, Ieva Tolmane*, Krzysztof Tomaszewicz*, Jonas Valantinas*, Pierre Van Damme*, Adriaan J van der Meer*, Ingo van Thiel*, Hans Van Vlierberghe*, Adriana Vince*, Wolfgang Vogel*, Heiner Wedemeyer*, Nina Weis*, Vincent WS Wong*, Cesar Yaghi*, Ayman Yosry*, Man-fung Yuen*, Evy Yunihastuti*, Aasim Yusuf*, Eli Zuckerman*, Homie Razavi†. *Authors listed alphabetically. †Corresponding author.

Affiliations

Center for Disease Analysis (CDA), Lafayette, Colorado, US (S Blach MHS, C Estes MPH, I Gamkrelidze BA, I Gountas MSC, J Gunter MPH, K Murphy MSCS, H Nde MPH, K Pasini MBA, D Razavi-Shearer BS, K Razavi-Shearer BA, S Robbins MSPH, J D Schmelzer MPH, H Razavi PhD); Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany (Prof S Zeuzem MD); Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany (Prof M Manns MD); King Abdulaziz Medical City and King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia (I Altraif FRCP, A A Aljumah FRCP); Department of Infectious Diseases, Faculty of Medicine and Health, Örebro University, Örebro, Sweden (A Duberg PhD); School of Health and Medical Sciences, Örebro University, Sweden (A Duberg); Eijkman Institute for Molecular Biology; Jakarta, Indonesia (Prof D H Muljono MD); University of Sydney, Department of Hepatitis & Emerging Infectious Diseases, Sydney, NSW, Australia (Prof D H Muljono); National Liver Institute, Menoufiya, Egypt (Prof I Waked MD); Baqiatallah Research Center for Gastroenterology and Liver Diseases, Baqiatallah University of Medical Sciences, Tehran, Tehran, Iran (S M Alavian MD); Middle East Liver Diseases Centre, Tehran, Tehran, Iran (S M Alavian); Institute of Clinical Medicine, National Yang-Ming University, Taipei (Prof M H Lee PhD); Divisions of Gastroenterology and Hepatology and of Clinical Pathology,

- University Hospital, rue Gabrielle-Perret-Gentil 4, Geneva, Switzerland (Prof F Negro MD); Department of Liver and Small Bowel Transplantation, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia (F Abaalkhail MD); Rashid Hospital, Dubai Health Authority, United Arab Emirates (A Abdou FRCP); Salmaniya Medical Complex, Bahrain (M Abdulla MRCP, J Khamis MD); National Hepatitis Program, Ministry of Public Health, Lebanon (A Abou Rached MD); Department of Infectious Diseases, Helsinki University Central Hospital, Finland (I Aho MD); Gastroenterology, Ege University, Izmir, Turkey (Prof U Akarca MD); GI and hepatology department, Jordan Royal Medical Services, Jordan (I Al Ghazzawi FRCP); Division of Gastroenterology, Department of Medicine, Hamad Medical Corporation, Doha, Qatar (S Al Kaabi MD, O Hajlssedig MD, Y Kamel MD, M Sharma DM); Royal Hospital, Ministry of Health, Oman (F Al Lawati MD); Department of Medicine, Division of Gastroenterology and Hepatology, Armed Forces Hospital, Muscat, Oman (K Al Namaani FRCP); Hospitals Sector, Ministry of Health, United Arab Emirates (Y Al Serkal MSc); Division of Gastroenterology, Department of Medicine, Sultan Qaboos University Hospital, Muscat, Oman (S A Al-Busafi MD); Infectious Diseases Unit, Rashid Hospital, Dubai Health Authority, United Arab Emirates (L Al-Dabal MD); Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden (S Aleman MD); Department of Gastroenterology and Hepatology/Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden (S Aleman); Gastroenterology Unit, Medical Department, King Fahad Hospital, Jeddah, Saudi Arabia (A S Alghamdi MD); Public Health Department, Supreme Council of Health, Doha, Qatar (H E Al-Romaihi MD); Division of Medical Virology, Department of Pathology, Stellenbosch University, Faculty of Health Sciences, South Africa (M I Andersson MD); Centre Hospitalier de Luxembourg, Luxembourg (V Arendt MD); Luxembourg Institute of Health, Esch sur Alzette, Luxembourg (V Arendt); Department of Gastroenterology, Helsinki University Central Hospital, Helsinki, Finland (P Arkkila MD); Department of Preventive Medicine, Ministry of Health, Riyadh, Saudi Arabia (A M Assiri MD); Department of Infectious Diseases, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia (Prof O Baatarkhuu MD); Addis Ababa University College of Health Sciences Medical School, Addis Ababa, Ethiopia (A Bane MD); Liver Disease Center, Sheba Medical Center, Tel Hashomer, Israel (Prof Z Ben-Ari MD); St James's Hospital, Dublin, Ireland (Prof C Bergin MD, Prof S Norris PhD); Trinity College, Dublin, Ireland (Prof C Bergin, Prof S Norris); University of Rosario School of Medicine, Rosario, Argentina (F Bessone MD); Gastroenterology Department, Ospedale Cantonale, Bellinzona (F Bihl MD); Faculty of Medicine, Division of Infectious Diseases, American University of Beirut Medical Center, Lebanon (A R Bizri MD); Paris, France (M Blachier MD, H Leleu MD); Madrid, Spain (A J Blasco PhD); Department of Gastroenterology, Federal University of the State of Rio de Janeiro (Universidade Federal do Estado do Rio de Janeiro), Rio de Janeiro, RJ, Brazil (C E Brandão Mello MD); Arud Centres for Addiction Medicine, Zurich, Switzerland (P Bruggmann MD); Canterbury District Health Board, Christchurch, New Zealand (C R Brunton MD); Gastroenterology Department, Centro Hospitalar de Lisboa Central—Hospital Santo António Capuchos, Lisbon, Portugal (F Calinas MD); Department of Medicine and Therapeutics, The Chinese University of Hong Kong (Prof H L Y Chan MD); Gujranwala Liver Foundation, Siddiq Sadiq Hospital, Gujranwala, Pakistan (A Chaudhry FRCP); Hospital das Clínicas da Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil (Prof H Cheinquer MD); Academia Sinica, Taipei (Prof C J Chen ScD); Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan (Prof R N Chien MD); Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (Prof M S Choi MD); Department of Infectious Diseases, Odense University Hospital, Odense, Denmark (Prof P B Christensen MD, A L H Øvrehus MD); Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan (Prof W L Chuang MD); Reference Center for Viral Hepatitis, Central Research Institute of Epidemiology, Moscow, Russia (V Chulanov MD, N Pimenov MD); UMAE # 25 Instituto Mexicano del Seguro Social Monterrey N.L. México (L Cisneros MD); Department of Hepatology, Rigshospitalet, University of Copenhagen, Denmark (M R Clausen DSc); Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK (Prof M E Cramp MD); Gastroenterology and Hepatology, Department of Internal Medicine and Medical Specialities (Di.Bi.M.I.S.); University of Palermo, Palermo, Italy (Prof A Craxi MD); Gastroenterologia and Epatologia, Azienda Ospedaliera Universitaria Policlinico, Palermo, Italy (Prof A Craxi); Trimbos Institute, Utrecht, Netherlands (E A Croes MD); Department of Infectious Diseases, Akershus University Hospital, Oslo, Norway (Prof O Dalgard PhD); Sección Hepatología, Hospital de Clínicas San Martín, GEDYT, Argentina (J R Daruich MD); Universidad de Buenos Aires, Buenos Aires, Argentina (J R Daruich MD); Service d'Hépatogastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, Pessac, France (Prof V de Ledinghen MD); INSERM U1053, Université Bordeaux Segalen, Bordeaux, France (Prof V de Ledinghen); Kirby Institute, University of New South Wales, Sydney, NSW, Australia (Prof G J Dore PhD, J Grebely PhD, B Hajarizadeh PhD); Ain Shams University, Cairo, Egypt (Prof M H El-Sayed DPM); Public Health and Epidemiology, Dokuz Eylül University, Izmir Turkey (G Ergör MD); Cairo University, Cairo, Egypt (G Esmat MD, A Yosry MD); Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (K Falconer MD); Public Health Department, Ministry of Public Health, Doha, Qatar (E Farag MPH); Division of Gastroenterology, Federal University of Sao Paulo, Sao Paulo, Brazil (Prof M L G Ferraz MD); Division of Infectious Disease, Federal University of São Paulo (Prof P R Ferreira MD); Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland (Prof R Flisiak); Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic (S Frankova MD, J Sperl MD); Auckland Hospital Clinical Studies Unit, Auckland, New Zealand (E Gane MD); Hospital Universitario La Paz, CIBERehd, IdiPAZ, Madrid, Spain (J García-Samaniego MD); Department of Gastroenterology & Hepatology, Lady Reading Hospital, Peshawar, Pakistan (A G Khan MD); Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania (A Goldis MD); Faculty of Medicine, School of Health Sciences, Landspítali—The National University Hospital of Iceland, Reykjavik, Iceland (M Gottfredsson MD); Wilhelminenspital, Department of Internal Medicine IV, Vienna, Austria (Prof M Gschwanter); Division of Gastroenterology and Hepatology, University of São Paulo School of Medicine, São Paulo, Brazil (M Guimarães Pessoa MD); The Aga Khan University, Karachi, Pakistan (Prof S Hamid FRCP); Jordan Ministry of Health (W Hamoudi MD); Department of Hygiene, Epidemiology and Medical Statistics, Athens University Medical School, Athens, Greece (Prof A Hatzakis MD, V Sympa PhD); Hellenic Scientific Society for the Study of AIDS and Sexually Transmitted Diseases, Athens, Greece (Prof A Hatzakis); Public Health Department, Ministry of Public Health, Doha, Qatar (S M Himatt MD); Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria (Prof H Hofer MD); General Hospital Pula, Pula, Croatia (I Hrstic PhD); Queen Elizabeth Hospital, Hong Kong (Y T Hui FRCP); Department of Gastroenterology, Somogy County Kaposi Mor Teaching Hospital, Kaposvar, Hungary (B Hunyady MD); First Department of Medicine, University of Pecs, Pecs, Hungary (B Hunyady); Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey (Prof R Idilman); Aga Khan University, Karachi, Pakistan (Prof W Jafri FRCP); Disease Control Division, Ministry of Health Malaysia, Putrajaya, Malaysia (R Jahis MPH); British Columbia Centre for Disease Control (BCCDC), Vancouver, BC, Canada (N Z Janjua, M Kraiden); School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (N Z Janjua); 1st Department of Internal Medicine, Medical Faculty, PJ Šafárik University, Kosice, Slovak Republic (P Jarčuška MD); Out-patient Department, Latvian Infectology Centre, Riga East University Hospital, Riga, Latvia (A Jeruma PhD); Department of Infectology and Dermatology, Riga Stradins University, Riga, Latvia (A Jeruma); Department of Pathology, Landspítali - The National University Hospital of Iceland, Reykjavik, Iceland (Prof J G Jonasson MD); Faculty of Medicine, University of Iceland,

Reykjavik, Iceland (Prof J G Jonasson); Department of Medicine, Miniya University, Egypt (Y Kamel MD); Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan (Prof J H Kao MD); Gastroenterology, Istanbul University, Istanbul, Turkey (Prof S Kaymakoglu MD); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico (Prof D Kershenobich MD); Department of Internal Medicine, Soon Chun Hyang University Bucheon Hospital, Bucheon, Korea (Prof Y S Kim MD); Therapeutic Research and Medicines Evaluation Department, Istituto Superiore di Sanità, Rome, Italy (L Kondili PhD); Digestive Disease Institute, Cleveland Clinic Abu Dhabi, United Arab Emirates (Z Koutoubi MD); Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada (M Krajden); Department of Medical Gastroenterology and Section of Molecular Diagnostics, Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark (H Krarup PhD); Department of Medicine, North District Hospital, Hong Kong (M S Lai FRCP); University Hospitals Leuven, KU Leuven, Leuven, Belgium (W Laleman MD); Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong (W C Lao Bach); Consultant, Ruelle des Chataigniers 1, Denges VD, Switzerland (D Lavanchy MD MHEM); Madrid, Spain (P Lázaro PhD); Medicine & Gastroenterologist, University of Lagos and Lagos University Teaching Hospital PMB, Idi-Araba, Lagos, Nigeria (O Lesi MBCH); Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia (L A Lesmana MD); Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia (L A Lesmana); Division of Gastroenterology and Hepatology, Department of Medicine and Geriatrics, Tuen Mun Hospital, Hong Kong SAR (M Li FRCP); Centre of Hepatology, Gastroenterology, and Dietetics, Faculty of Medicine, Vilnius University, Vilnius, Lithuania (V Liakina PhD, D Speiciene MD, Prof J Valantinas MD); Department of Biomechanics, Vilnius Gediminas Technical University, Vilnius, Lithuania (V Liakina); Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Seoul, Korea (Prof Y S Lim MD); Clinical Department of Infectious Diseases, Split University Hospital and Split University Medical School, Soltanska 1, Split, Croatia (Prof B Luksic PhD); Department of Internal Medicine, University of Witwatersrand, Johannesburg, South Africa (A Mahomed FCP SA); University of Tartu, Tartu University Hospital, Tartu, Estonia (M Maimets PhD, Prof R Salupere PhD); Central Outpatient Clinic, Saint Laszlo Hospital, Budapest, Hungary (M Makara MD); Benue State University Teaching Hospital, Makurdi, Nigeria (A O Malu FMCP); Gastroenterology Department, Centro Hospitalar de Lisboa Norte, Hospital Santa Maria, Lisbon, Portugal (R T Marinho MD); Division of Gastroenterology, University of Western Ontario, London, ON, Canada (P Marotta MD); Center for HIV and Hepatogastroenterology, Duesseldorf, Germany (S Mauss MD); Asian Institute of Medical Science (AIMS), Hyderabad, Sindh, Pakistan (M S Memon FCPS); School of Medicine, Universidade de São Paulo, Brazil (Prof M C Mendes Correa MD); Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico (Prof N Mendez-Sanchez MD); Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran (Prof S Merat); Community Medicine Research Department, National Research Center- Egypt (Prof A M Metwally PhD); University of Malaya Medical Centre, Kuala Lumpur, Malaysia (Prof R Mohamed MD); CUB Hôpital, Erasme, Université Libre de Bruxelles, Brussels (Prof C Moreno MD); Division of Gastroenterology, American University of Beirut Medical Center, Lebanon (Prof F H Mourad MD, Prof A I Sharara MD); Swiss HPB (Hepato-Pancreato-Biliary) Center and Department of Gastroenterology and Hepatology, University Hospital Zürich, Switzerland (Prof B Müllhaupt); Virology Department, Centre Pasteur of Cameroon, Yaounde, Cameroon (Prof R Njouom PhD); Institute of Public Health County of Dalmatia, Department of Epidemiology, Croatia (D Nonkovic MSc); Advocacy for The Prevention of Hepatitis in Nigeria, Nigeria (S Obekpa MBBS); Benue State University Teaching Hospital, Makurdi, Nigeria (S Obekpa); Paediatrics Department, Faculty of Medical Sciences, University of Jos, Jos, Nigeria (Prof S Ogueche FMCPaed); Jos University Teaching Hospital, Jos, Jos, Nigeria (Prof S Ogueche); Division of Gastroenterology and Hepatology, Landspítali, The National University Hospital of Iceland, Reykjavik, Iceland (S Olafsson MD); Gastroenterology and Hepatology Center, Bratislava, Slovakia (M Oltman MD); Federal Ministry of Health, Nigeria (O Omede MPH); University of Benin (C Omuemu FWACP); Kwame Nkrumah University of Science and Technology, Kumasi, Ghana (Prof O Opare-Sem MD, R O Phillips MD); Komfo Anokye Teaching Hospital, Kumasi, Ghana (S Owusu-Ofori MBCHB); Laboratory of Molecular Biology, Institute of Biology, Mongolian Academy of Sciences, Ulaanbaatar, Mongolia (T S Oyunsuren ScD); Department of Gastroenterology, Medical School of National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece (Prof G Papatheodoridis PhD); Departments of Medicine and Surgery, Dalhousie University, and Hepatology Services, Queen Elizabeth II Health Sciences Centre, Capital District Health Authority, Halifax, NS, Canada (K M Peltekian MD); Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran (H Poustchi MD); Center for Vaccines and Immunology, National Institute for Communicable Diseases, Johannesburg, South Africa (N Prabdial-Sing PhD); Division of Virology and Communicable Diseases Surveillance, School of Pathology, University of Witwatersrand, Johannesburg, South Africa (N Prabdial-Sing); Pakistan Medical Research Council, Islamabad, Pakistan (H Qureshi MD); Department of Gastroenterology, University of British Columbia, Vancouver, BC, Canada (A Ramji MD); St Paul Hospital's Millennium College Vice Provost, GI Association, Addis Ababa, Ethiopia (B Redae MD); Department of Hepatology, Academic Medical Center, Amsterdam, Netherlands (H W Reesink MD); Hepatology Section, Department of Medicine, Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno (CEMIC), Buenos Aires, Argentina (E Rídruejo MD); Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA (L R Roberts MB); The Alfred Hospital and Monash University, Melbourne, VIC, Australia (Prof S K Roberts MD); UCL Institute for Liver and Digestive Health, Division of Medicine, University College London, London, UK (Prof W M Rosenberg DPhil); Département Santé Publique, Hôpital Henri Mondor, Créteil, France (F Roudot-Thoraval MD); Nottingham Digestive Diseases Centre and NIHR Biomedical Research Unit, Nottingham University Hospitals NHS Trust and the University of Nottingham (S D Ryder DM); Liver Unit, Hadassah Medical Center, Jerusalem, Israel (Prof R Safadi MD); Infectious Diseases Department, Clinic of the South Ural State Medical University, Chelyabinsk, Russia (O Sagalova MD); Division of Gastroenterology, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia (M Sanai SBG); Liver Disease Research Center, King Saud University, Riyadh, Saudi Arabia (F M Sanai SBG); Departamento de Gastroenterología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Vasco de Quiroga No 15, Delegación Tlalpan, México DF, México (J F Sanchez Avila MD); Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India (V Saraswat DM); Infectious Diseases Department, Centro Hospitalar do Porto, Porto, Portugal (R Sarmento-Castro PhD); JW Goethe University Hospital, Frankfurt, Germany (Prof C Sarrazin MD); Department of Infectology and Travel Medicine, Medical Faculty, PJ Šafárik University, Kosice, Slovak Republic (Prof I Schréter MD); Department of Infection and Immunity, Luxembourg Institute of Health, Esch sur Alzette, Luxembourg (C Seguin-Devaux PhD); Department of Hepatology, Institute of Liver Diseases, HPB Surgery and Liver Transplant, Global Hospitals, Mumbai, India (S R Shah DM); Department of Infectious and Parasitic Diseases with Immunoprophylaxis, St Petersburg Polyclinic 74, St Petersburg, Russia (A Shevaldin PhD); Infectious disease and General Medicine, Sen Sok International University Hospital, Phnom Penh, Cambodia (A Shevaldin PhD); Egyptian Liver Research Institute And Hospital (ELRIAH), Dakahliah, Egypt (Prof G E Shiha MD); Monash University and Monash Health, Melbourne, VIC, Australia (Prof W Sievert MD); Division of Hepatology, Department of Medicine, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa (Prof M Sonderup FCP); Faculty of Social and Political Sciences, University of Peloponnese, Corinth, Greece and Centre for Health Services (Prof K Souliotis PhD); Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCL), Brussels, Belgium

(Prof P Stärkel MD); Division of Gastroenterology and Hepatology, Department of Internal Medicine, Medical University of Graz, Graz, Austria (Prof R E Stauber MD); Christchurch Hospital and University of Otago, Christchurch, New Zealand (C Stedman PhD); Department of Population Health, Luxembourg Institute of Health, Strassen, Luxembourg (D Struck MSc); Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan (T H Su MD); Department of Hepatology, Selayang Hospital, Selangor, Malaysia (S S Tan MRCP); Department of Epidemiology, Infectious Disease Control and Prevention, Institute of Biomedical and Health Sciences, Hiroshima, Hiroshima University, Japan (Prof J Tanaka PhD); Department of Gastroenterology, St Vincent's Hospital and the University of Melbourne, Melbourne, VIC, Australia (Prof A J Thompson PhD); Department of Hepatology, Infectology Center of Latvia, Riga East University Hospital, Riga, Latvia (I Tolmane PhD); Department of Medicine, Latvian University, Riga, Latvia (I Tolmane PhD); Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland (K Tomasiewicz PhD); Universiteit Antwerpen, Antwerpen, Belgium (Prof P Van Damme PhD, Prof H Van Vlierberghe MD); Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands (A J van der Meer MD); Deutsche Leberhilfe e.V., Köln, Germany (I van Thiel Magister); European Liver Patients Association, Sint-Truiden, Belgium (I van Thiel Magister); Medical School University of Zagreb, University Hospital of Infectious Diseases Zagreb, Zagreb, Croatia (A Vince MD); Division of Gastroenterology and Hepatology, Department Internal Medicine, Medical University Innsbruck, Austria (Prof W Vogel MD); Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany (Prof H Wedemeyer MD); German Liver Foundation, Germany (Prof H Wedemeyer); Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark (N Weis MD); Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark (N Weis); Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong (V WS Wong MD); State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong (V WS Wong); Department of Hepatology and Gastroenterology, School of Medical Science, Saint Joseph University, Beirut, Lebanon (C Yaghi MD); Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong (Prof M Yuen MD); Division of Clinical Immunology, Department of Medicine, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia (E Yuniastuti PhD); Shaikat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan (A Yusuf FRCP Edin); and Liver Unit, Carmel University Medical Center, Bruce Rappaport Faculty of Medicine, Technion, Israeli Institute of Technology, Haifa, Israel (E Zuckerman).

Declaration of interests

SB, CE, IG, IGA, JGu, KM, HN, KP, DR-S, KR-S, SR, JDS, and HR report grants from the John C Martin Foundation, Gilead Sciences, AbbVie, WHO, and the US National Academy of Sciences during the conduct of the study; and grants from Intercept Pharmaceuticals and Boehringer Ingelheim outside of the submitted work. SZ reports personal fees from AbbVie, BMS, Gilead, Janssen, and Merck, outside of the submitted work. MM reports grants and personal fees from Roche, Bristol-Myers Squibb, Gilead, Boehringer Ingelheim, Novartis, Merck (MSD), and Janssen, personal fees from Idenix, grants and personal fees from GlaxoSmithKline and Biotest, and personal fees from Achillion outside of the submitted work. IA reports support for travel to international conferences from Roche, GlaxoSmithKline, BMS, AbbVie, Biopharma, Merck, and Janssen outside of the submitted work. IW reports grants and non-financial support from AbbVie, Gilead, Janssen, and Roche, grants from Pharco, Mylan, Onxio, and BMS, outside of the submitted work. ML reports personal fees from Gilead Sciences, personal fees from AbbVie and Bristol-Myers Squibb, and funding from the Ministry of Science and Technology, Taipei, Taiwan, outside of the submitted work. FN reports grants and personal fees from Gilead and AbbVie, personal fees from Merck and Bristol Myers Squibb, outside of the submitted work. IA reports grants from BMS Virology, and personal fees from AbbVie, BMS, Gilead, GSK, and MSD, outside of the submitted work. UA reports personal fees from BMS and

Gilead, outside of the submitted work. MB reports grants from Gilead Sciences, during the conduct of the study; and grants from Gilead Sciences outside of the submitted work. PB reports grants and personal fees from AbbVie, BMS, Merck, and Gilead, outside of the submitted work. FC reports personal fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Boehringer Ingelheim, Merck Sharp and Dohme, and Janssen, outside of the submitted work. HLYC reports personal fees from AbbVie, Gilead, and Bristol-Myer Squibb, grants and personal fees from Roche, personal fees from Novartis, Echosens, and Janssen, outside of the submitted work. PBC reports grants from Gilead, AbbVie, and Merck Sharp & Dohme, outside of the submitted work. VC reports personal fees from AbbVie, grants and personal fees from BMS, and personal fees from Gilead, Janssen, Merck/MSD, and Roche, outside of the submitted work. LC reports personal fees from Bristol, AbbVie, Bayer, and Roche outside of the submitted work. MEC reports grants, personal fees, and non-financial support from AbbVie, BMS, Gilead, Merck, and Janssen, outside of the submitted work. OD reports grants and personal fees from Merck, grants from Gilead, and grants and personal fees from AbbVie, during the conduct of the study. VdL reports personal fees from AbbVie, Gilead, BMS, and Merck, during the conduct of the study. GJD reports grants from AbbVie, Merck, Bristol-Myers Squibb, Janssen, Roche, and personal fees from Gilead, AbbVie, Merck, Bristol-Myers Squibb, Janssen, Roche, GlaxoSmithKline, and Abbott Diagnostics, and non-financial support from Gilead, AbbVie, Merck, Bristol-Myers Squibb, and Roche, outside of the submitted work. MHE reports support for flight and accommodation to international meetings without honoraria or per-diem among Egyptian delegates attending the meetings from AbbVie, Quadri-pharma, and MSD, outside of the submitted work. GE reports grants from Gilead, AbbVie, and BMS, support for flight and accommodation to international meetings without honoraria or per-diem among Egyptian delegates attending the meetings from Janssen, GSK, Roche, and MSD, during the conduct of the study. RF reports grants, personal fees, and non-financial support from AbbVie and Gilead, personal fees and non-financial support from Merck, grants, personal fees, and non-financial support from Roche, personal fees and non-financial support from Janssen, personal fees and non-financial support from Bristol-Myers Squibb, and personal fees from Novartis, outside of the submitted work. JGS reports grants and personal fees from Gilead, and personal fees from AbbVie, Janssen, and Bristol-Myers-Squibb, outside of the submitted work. JGr reports grants from AbbVie and Bristol-Myers Squibb, and grants and personal fees from Gilead Sciences and Merck, outside of the submitted work. MG reports grants and personal fees from Gilead and AbbVie, personal fees from BMS, MSD, and Janssen, outside of the submitted work. MGP reports grants and personal fees from AbbVie, and personal fees from BMS, Alexion, MSD, and Gilead, outside of the submitted work. HH reports grants from AbbVie, personal fees from Gilead, MSD, and AbbVie, outside of the submitted work. MK reports grants from Roche, Merck, Siemens, Hologic, and Boehringer, outside of the submitted work. HL reports payments to his company related to work done for Gilead, during the conduct of the study. MM reports being an investigator in clinical trials for Novartis, Bristol-Myers Squibb, Janssen-Cilag, AbbVie, Roche, Boehringer Ingelheim, Merck Sharp & Dohme, and Regulus, personal fees from Janssen-Cilag, AbbVie, Roche, Boehringer Ingelheim, Merck Sharp & Dohme, and Gilead, outside of the submitted work. RTM reports personal fees and non-financial support from Gilead, AbbVie, MSD, and BMS, outside of the submitted work. SM reports personal fees from Gilead, BMS, Janssen, and ViiV, and grants and personal fees from AbbVie, outside of the submitted work. CM reports grants and personal fees from AbbVie and Gilead, personal fees from BMS, grants and personal fees from Janssen, personal fees from Merck, and grants from Roche, outside of the submitted work. BM reports grants and personal fees from Roche, personal fees from MSD, Janssen, AbbVie, and Boehringer, grants and personal fees from Gilead, and personal fees from BMS, during the conduct of the study. ALHØ reports grants, personal fees, and non-financial support from Gilead Sciences, during the conduct of the study. AR reports grants and personal fees from AbbVie, BMS, Gilead, Janssen, and Merck, and personal fees from Lupin, outside of the submitted work. HWR reports grants, personal fees, and non-financial support from AbbVie, personal fees from Alnylam, grants, personal

fees, and non-financial support from BMS, grants and personal fees from Boehringer Ingelheim, grants, personal fees, and non-financial support from Gilead, grants, personal fees, and non-financial support from Janssen-Cilag, grants and personal fees from Merck/MSD, PRA-International, and Regulus, and grants from Replicor, grants and personal fees from Roche, and personal fees from R-Pharm, outside of the submitted work. LRR reports grants from Gilead Sciences, BTG International, Wako Diagnostics, and Ariad Pharmaceuticals, outside of the submitted work. FR reports personal fees and non-financial support from Roche, BMS, Gilead, and AbbVie, outside of the submitted work. OS reports grants from MSD, and RPharm, personal fees from BMS and AbbVie (as a lecturer), grants from AbbVie, grants from MSD and personal fees from Gilead (as a lecturer), outside of the submitted work. RS reports personal fees and non-financial support from MSD/Merck, grants, personal fees, and non-financial support from AbbVie Biopharmaceuticals, grants from Gilead Sciences, non-financial support from Takeda Pharma, and grants from Intercept Pharmaceuticals, outside of the submitted work. FMS reports personal fees and non-financial support from Gilead Sciences, grants, personal fees, and non-financial support from AbbVie, and personal fees and non-financial support from Merck Sharpe Dohme, outside of the submitted work. JFSA reports grants from Janssen de México, grants from AbbVie Farmaceuticos, personal fees from Bayer Health Care México, and personal fees from AbbVie Farmaceuticos, outside of the submitted work. RS reports personal fees from Gilead, Janssen, AbbVie, BMS, and MSD, outside of the submitted work. CS reports personal fees from AbbVie, Abbott, BMS, Gilead, Janssen, and Merck, and grants from Abbott, Gilead, Janssen, and Siemens, outside of the submitted work. WS reports personal fees from MSD, BMS, and Gilead, outside of the submitted work. MS reports grants from Gilead and personal fees from AbbVie, outside of the submitted work. PS reports grants and personal fees from Gilead, AbbVie, and BMS, and personal fees from MSD, outside of the submitted work. RES reports grants and personal fees from AbbVie, and personal fees from BMS, Gilead, and MSD, outside of the submitted work. CS reports personal fees and non-financial support from Gilead Sciences, AbbVie, and MSD, outside of the submitted work. VS reports personal fees from Gilead and AbbVie, outside of the submitted work. AJT reports grants and personal fees from Gilead Sciences, Merck, AbbVie, and BMS, outside of the submitted work. KT reports grants and personal fees from Gilead, and personal fees from Merck, BMS, AbbVie, and Roche, outside of the submitted work. PVD reports grants from Viral Hepatitis Prevention Board, during the conduct of the study; and grants from Bill & Melinda Gates Foundation, outside of the submitted work. AJvdm reports personal fees from Gilead and AbbVie, outside of the submitted work. HW reports grants and personal fees from AbbVie, Abbott, Gilead, Roche, Roche Diagnostics, and Eisai, grants from Myr GmbH, personal fees from BMS, Novartis, MSD/Merck, Janssen, Transgene, and Boehringer Ingelheim during the conduct of the study; and personal fees from AbbVie, Abbott, BMS, Boehringer Ingelheim, Gilead, Eisai, Roche, Novartis, Myr GmbH, Boehringer Ingelheim, Siemens, Janssen, Omniamed, Falk Foundation, and MedUpdate, outside of the submitted work. NW reports personal fees from AbbVie, Bristol-Myers Squibb, Gilead, and Merck Sharp Dohme, outside of the submitted work. VWW reports personal fees from AbbVie, Gilead Sciences, Merck, NovoMedica, Echosens, and Novartis, and Roche, outside of the submitted work. All other authors declare no competing interests.

Acknowledgments

This study was funded by the John C Martin Foundation through the Polaris Observatory. We also acknowledge The Ministry of Science and Technology, Taipei, Taiwan (MOST 104-2628-B-010-001-MY3 and MOST 105-2628-B-010-003-MY4) for their work on the Taiwan analysis.

References

- Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. *Lancet* 2016; **388**: 1081–88.
- Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. *Aliment Pharmacol Ther* 2016; **46**: 1276–92.
- Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian S, Malekzadeh R, Razavi AH. Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden. *Hepat Mon* 2016; **16**: e37234.
- Sharma SA, Feld JJ. Acute hepatitis C: management in the rapidly evolving world of HCV. *Curr Gastroenterol Rep* 2014; **16**: 371.
- Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology* 2015; **61**: 77–87.
- Au TH, Destache CJ, Vivekanandan R. Hepatitis C therapy: Looking toward interferon-sparing regimens. *J Am Pharm Assoc* 2015; **55**: e72–84.
- Gane E, Kershenobich D, Seguin-Devaux C, et al. Strategies to manage hepatitis C virus (HCV) infection disease burden—volume 2. *J Viral Hepat* 2015; **22**: 46–73.
- Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. *Hepatology* 2016; **64**: 1442–50.
- Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. *Hepatology* 2015; **61**: 1471–78.
- Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. *J Viral Hep* 2015; **23**: 217–26.
- Younossi ZM, Stepanova M, Henry L, et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. *J Viral Hep* 2016; **23**: 623–30.
- Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. *Gastroenterology* 2016; **150**: 1599–608.
- Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. *J Infect Dis* 2012; **206**: 469–77.
- Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. *Gastroenterology* 2015; **149**: 1345–60.
- Assembly WHOS-NWH. Draft Global Health Sector Strategies Viral Hepatitis 2016–2021, 2016. http://www.who.int/hepatitis/strategy2016-2021/Draft_global_health_sector_strategy_viral_hepatitis_13nov.pdf (accessed Nov 29, 2016).
- WHO. Combating Hepatitis B and C to Reach Elimination by 2030. Geneva: World Health Organization, 2016.
- Saraswat V, Norris S, de Knecht RJ, et al. Historical epidemiology of hepatitis C virus (HCV) in select countries—volume 2. *J Viral Hepat* 2015; **22**: 6–25.
- WHO. World Hepatitis Summit harnesses global momentum to eliminate viral hepatitis. Geneva: WHO, 2015. <http://www.who.int/mediacentre/news/releases/2015/eliminate-viral-hepatitis/en/> (accessed Sept 15, 2015).
- Ministry of Health and Population, Egypt. E-ZaA, ICF International. Egypt Health Issues Survey 2015. Cairo, Egypt and Rockville, MD, USA, 2015. <https://dhsprogram.com/pubs/pdf/FR313/FR313.pdf> (accessed Nov 29, 2016).
- Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. *J Hepatol* 2014; **61**: S45–S57.
- Lavanchy D. The global burden of hepatitis C. *Liver Int* 2009; **29**: 74–81.
- Lavanchy D. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect* 2011; **17**: 107–15.
- Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. New estimates of age-specific antibody to HCV seroprevalence. *Hepatology* 2013; **57**: 1333–42.
- Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat* 2014; **21**: 34–59.
- Sibley A, Han KH, Abourached A, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm—volume 3. *J Viral Hepat* 2015; **22**: 21–41.

- 26 Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm—volume 2. *J Viral Hepat* 2015; **22**: 26–45.
- 27 Malcolm DG, Roseboom JH, Clark CE, Fazar W. Application of a technique for research and development program evaluation. *Oper Res* 1959; **7**: 646–69.
- 28 Chen YS, Li L, Cui FQ, et al. A sero-epidemiological study on hepatitis C in China. *Zhonghua liu xing bing xue za zhi* 2011; **32**: 888–91.
- 29 Hong TP, Gow P, Fink M, et al. Novel population-based study finding higher than reported hepatocellular carcinoma incidence suggests an updated approach is needed. *Hepatology* 2016; **63**: 1205–12.
- 30 Torner A, Stokkeland K, Svensson A, et al. The underreporting of hepatocellular carcinoma to the cancer register and a log-linear model to estimate a more correct incidence. *Hepatology* 2016; published online Aug 17. DOI:10.1002/hep.2877.